Literature DB >> 18535172

Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?

Salvador Vale1.   

Abstract

Parkinson's disease (PD) clinical features comprise both motor and nonmotor manifestations. Among the nonmotor complications, dementia is the most important. Approximately 40% of PD patients are affected by cognitive impairment. Remarkably, in addition to age, dementia is an independent predictor of mortality, whereas age at onset of PD and severity of neurological symptoms are not. In this review, I summarize the current knowledge of the pathogenesis of the PD cognitive impairment in relation to the therapies presently accessible and those that could become strategic in the near future. It is hypothesized that patients with PD show two components of cognitive dysfunction (CD): a generalized profile of subcortical dementia (PDsCD), and an overlapped pattern suggesting specific prefrontal damage with CD (PDpFCD). PDsCD is associated with structural neocortical/subcortical changes in the brain (in frontal, parietal, limbic, and temporal lobes, as well as in midbrain structures). In PDpFCD cognitive deficits comprise impairments in neuropsychological tests sensitive for frontal lobe function (discrete elements of episodic and working memory for instance), which are considered to be the consequence of dysfunction in neuronal loops connecting the prefrontal cortex and basal ganglia. Drugs reviewed for targeting PDsCD include: cholinesterase inhibitors, agents with mixed cholinergic and dopaminergic properties, antiglutamatergic drugs, mixed antiglutamatergic/dopaminergic agents; antioxidants and enhancers of mitochondrial functions, and anti-COX-2, as well as other anti-inflammatory mediators. Preliminary studies with vehicles that may target PDpFCD include piribedil, tolcapone, amantadine, and farampator. Additional agents (citicoline and neuroimmuniphilines, among others) will be outlined. A brief overview on neuroprotection and promising new biological advances in PD (deep brain stimulation, stem cells, gene therapy) also will be summarized.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18535172     DOI: 10.3181/0707-MR-193

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  7 in total

1.  Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected].

Authors:  Bernardino Ossola; Nadia Schendzielorz; Shih-Heng Chen; Gary S Bird; Raimo K Tuominen; Pekka T Männistö; Jau-Shyong Hong
Journal:  Neuropharmacology       Date:  2011-05-11       Impact factor: 5.250

2.  Medical management of Parkinson's disease: focus on neuroprotection.

Authors:  Marie-Catherine Boll; Mireya Alcaraz-Zubeldia; Camilo Rios
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

3.  Cognitive rehabilitation for executive dysfunction in Parkinson's disease: application and current directions.

Authors:  Jessica Calleo; Cristina Burrows; Harvey Levin; Laura Marsh; Eugene Lai; Michele K York
Journal:  Parkinsons Dis       Date:  2011-11-02

Review 4.  Treatment of neurological and psychiatric disorders with deep brain stimulation; raising hopes and future challenges.

Authors:  Mohammad Sharif Sharifi
Journal:  Basic Clin Neurosci       Date:  2013

Review 5.  Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review.

Authors:  Luisa Colucci; Massimiliano Bosco; Antonio Rosario Ziello; Raffaele Rea; Francesco Amenta; Angiola Maria Fasanaro
Journal:  J Exp Pharmacol       Date:  2012-12-11

Review 6.  Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014.

Authors:  Daniel Glizer; Penny A MacDonald
Journal:  Parkinsons Dis       Date:  2016-09-05

7.  Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial.

Authors:  Luca Rossetti; Michele Iester; Laura Tranchina; Laura Ottobelli; Giulia Coco; Elisabetta Calcatelli; Chiara Ancona; Paola Cirafici; Gianluca Manni
Journal:  J Glaucoma       Date:  2020-07       Impact factor: 2.290

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.